RxDoctor Payments DataLook up a doctor →

Ara Hanissian, MD

Adolescent Medicine · Collierville, TNNPI 1679649271

Payments from drug & device makers

$25,969in general payments, 2019–2025

Across 1,961 payments — averaging $13.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$4K
  • AbbVie$3K
  • AstraZeneca$3K
  • Lilly USA, LLC$2K
  • Amgen$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • plus $11K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk272$3,671
AbbVie(2 entities)347$3,146
AstraZeneca123$2,809
Lilly USA, LLC196$2,234
Amgen(2 entities)73$1,426
Takeda Pharmaceuticals U.S.A., Inc.82$1,184
Boehringer Ingelheim63$954
Pfizer50$833
Bayer74$759
GSK72$696
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC41$666
Amarin Pharma, Inc.41$660
Johnson & Johnson57$654
Abbott27$585
Bausch Health US, LLC28$468
Biohaven Pharmaceuticals, Inc.16$383
Upsher-smith Laboratories LLC24$359
Arbor Pharmaceuticals, Inc.45$351
Daiichi Sankyo Inc.16$284
Axsome Therapeutics, Inc.12$266
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)14$260
Merck28$250
Kowa Pharmaceuticals America, Inc.47$237
Teva Pharmaceuticals USA, Inc.27$224
Phathom Pharmaceuticals, Inc.21$213
Sanofi-aventis U.S. LLC12$202
Shire North American Group Inc11$149
Ironwood Pharmaceuticals, Inc8$147
Biohaven Pharmaceutical Holding Company Ltd.14$144
Neos Therapeutics, LP21$120
Esperion Therapeutics, Inc.6$105
Dexcom, Inc.5$99
Hikma Pharmaceuticals USA6$92
Genentech USA, Inc.5$90
Exact Sciences6$89
Antares Pharma, Inc.4$85
Adlon Therapeutics L.p.5$78
IBSA Pharma Inc.4$76
Currax Pharmaceuticals LLC5$69
Harmony Biosciences LLC4$65
Supernus Pharmaceuticals, Inc.5$64
Mannkind Corporation4$60
Seqirus USA Inc2$57
Eisai Inc.3$56
Azurity Pharmaceuticals, Inc.3$56
Almatica Pharma LLC2$50
Corium, LLC4$48
Tris Pharma Inc3$47
Idorsia Pharmaceuticals US Inc3$40
Romark Laboratories, LC3$40
Evoke Pharma, Inc.2$35
Xeris Pharmaceuticals, Inc.2$35
Clarus Therapeutics Inc.1$21
Aimmune Therapeutics, Inc.1$21
Cranial Technologies, Inc1$19
Ultragenyx Pharmaceutical Inc.1$19
Iroko Pharmaceuticals, LLC1$15
Avion Pharmaceuticals1$15
Ironshore Pharmaceuticals Inc.1$14
Acella Pharmaceuticals, LLC1$14

How this compares

$25,969 in reported general payments places this provider in the 95th percentile of 34 adolescent medicine providers in Tennessee.

See all adolescent medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$472,097
Medicare patients
486
Services billed
33,757

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other adolescent medicine in Collierville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →